ID   MDS92
AC   CVCL_A647
SY   MDS-92; MyeloDysplastic Syndrome 1992
DR   BTO; BTO_0006228
DR   cancercelllines; CVCL_A647
DR   Cosmic; 690409
DR   Cosmic; 1465958
DR   Wikidata; Q54904833
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=7947263;
RX   PubMed=8547120;
RX   PubMed=9195772;
RX   PubMed=11108571;
RX   PubMed=19344951;
RX   PubMed=29955132;
WW   Info; ResearchGate; -; https://www.researchgate.net/post/Where_can_I_get_MDS92_and_MDS-L_cell_lines
CC   Population: Japanese.
CC   Characteristics: IL3 dependent.
CC   Doubling time: 80-90 hours (PubMed=7947263).
CC   Sequence variation: Mutation; HGNC; HGNC:1833; CEBPA; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000851673; Zygosity=Heterozygous (PubMed=29955132).
CC   Sequence variation: Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000219097; Zygosity=Heterozygous (PubMed=7947263; PubMed=29955132).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; c.672+1G>A; ClinVar=VCV000216078; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=29955132).
CC   Omics: Genomics; Whole exome sequencing.
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): PubMed=29955132
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 8
ST   D16S539: 9,10
ST   D18S51: 12,17
ST   D21S11: 30,32.2
ST   D3S1358: 15
ST   D5S818: 13
ST   D7S820: 11
ST   D8S1179: 11,13
ST   FGA: 23
ST   Penta D: 9
ST   Penta E: 16,18
ST   TH01: 6
ST   TPOX: 8,11
ST   vWA: 15,17
DI   NCIt; C3247; Myelodysplastic syndrome
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   52Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 10-04-25; Version: 17
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).
//
RX   PubMed=7947263; DOI=10.1111/j.1365-2141.1994.tb04904.x;
RA   Tohyama K., Tsutani H., Ueda T., Nakamura T., Yoshida Y.;
RT   "Establishment and characterization of a novel myeloid cell line from
RT   the bone marrow of a patient with the myelodysplastic syndrome.";
RL   Br. J. Haematol. 87:235-242(1994).
//
RX   PubMed=8547120; DOI=10.1111/j.1365-2141.1995.tb05391.x;
RA   Tohyama K., Tohyama Y., Nakayama T., Ueda T., Nakamura T., Yoshida Y.;
RT   "A novel factor-dependent human myelodysplastic cell line, MDS92,
RT   contains haemopoietic cells of several lineages.";
RL   Br. J. Haematol. 91:795-799(1995).
//
RX   PubMed=9195772; DOI=10.1016/s0925-5710(96)00563-4;
RA   Tohyama K.;
RT   "Human factor-dependent leukemia cell lines.";
RL   Int. J. Hematol. 65:309-317(1997).
//
RX   PubMed=11108571; DOI=10.1080/13684730050515787;
RA   Nakamura S., Ohnishi K., Yoshida H., Shinjo K., Takeshita A.,
RA   Tohyama K., Ohno R., Koide Y.;
RT   "Retrovirus-mediated gene transfer of granulocyte colony-stimulating
RT   factor receptor (G-CSFR) cDNA into MDS cells and induction of their
RT   differentiation by G-CSF.";
RL   Cytokines Cell. Mol. Ther. 6:61-70(2000).
//
RX   PubMed=19344951; DOI=10.1016/j.leukres.2009.03.005;
RA   Drexler H.G., Dirks W.G., MacLeod R.A.F.;
RT   "Many are called MDS cell lines: one is chosen.";
RL   Leuk. Res. 33:1011-1016(2009).
//
RX   PubMed=29955132; DOI=10.1038/s41375-018-0189-7;
RA   Kida J.-i., Tsujioka T., Suemori S.-i., Okamoto S., Sakakibara K.,
RA   Takahata T., Yamauchi T., Kitanaka A., Tohyama Y., Tohyama K.;
RT   "An MDS-derived cell line and a series of its sublines serve as an in
RT   vitro model for the leukemic evolution of MDS.";
RL   Leukemia 32:1846-1850(2018).
//